You are here

Lian Zhan Qi Tian capsules

Safety advisory

18 February 2014

Lian Zhan Qi Tian capsules pose a serious risk to your health and should not be taken.

The Therapeutic Goods Administration (TGA) has tested Lian Zhan Qi Tian capsules and found that they contain:

  • Image of the Lian Zhan Qi Tian packagingthe undeclared prescription substance sildenafil.
  • consumers are advised that sildenafil is a prescription-only substance (which is the active ingredient in the medicine Viagra).

The supply of Lian Zhan Qi Tian capsules is illegal.

Lian Zhan Qi Tian capsules have not been assessed by the TGA for quality, safety or efficacy as required under Australian legislation, and the place of manufacture is not approved by the TGA.

TGA investigations have shown that a number of people in Australia have bought the product online.

Image of the Lian Zhan Qi Tian capsule packagingInformation for consumers

  • Stop taking Lian Zhan Qi Tian capsules and take any remaining capsules to your local pharmacy for safe disposal.
  • If you have any concerns arising from your use of this product, consult your health care practitioner.

Action the TGA is taking

The TGA is working with Australian Customs and Border Protection Services (Customs) to help stop future shipments of Lian Zhan Qi Tian capsules from entering Australia.

If these capsules are found at the border by Customs they will be seized and destroyed.

The TGA is advising consumers to exercise extreme caution when purchasing medicines from unknown overseas Internet sites. Products purchased over the Internet:

  • may contain undisclosed and potentially harmful ingredients
  • may not meet the same standards of quality, safety and efficacy as those approved by the TGA for supply in Australia.

Report counterfeit medicines and medical devices

If you are worried about counterfeit medicines or medical devices, and want to report an issue, you can report the matter to the TGA:

Phone: 1800 020 653
Online: Report a perceived breach of the Therapeutic Goods Act or questionable practices relating to therapeutic products